Attached files
| file | filename |
|---|---|
| EX-3.2 - EX-3.2 - ALNYLAM PHARMACEUTICALS, INC. | d19384dex32.htm |
| EX-3.1 - EX-3.1 - ALNYLAM PHARMACEUTICALS, INC. | d19384dex31.htm |
| EX-21.1 - EX-21.1 - ALNYLAM PHARMACEUTICALS, INC. | d19384dex211.htm |
| EX-31.1 - EX-31.1 - ALNYLAM PHARMACEUTICALS, INC. | d19384dex311.htm |
| EX-31.2 - EX-31.2 - ALNYLAM PHARMACEUTICALS, INC. | d19384dex312.htm |
| EX-32.1 - EX-32.1 - ALNYLAM PHARMACEUTICALS, INC. | d19384dex321.htm |
| EX-32.2 - EX-32.2 - ALNYLAM PHARMACEUTICALS, INC. | d19384dex322.htm |
| 10-K - FORM 10-K - ALNYLAM PHARMACEUTICALS, INC. | d19384d10k.htm |
| EX-10.12 - EX-10.12 - ALNYLAM PHARMACEUTICALS, INC. | d19384dex1012.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statement on Forms S-8 (Nos. 333-190498, 333-127450, 333-116151, 333-148114, 333-157633, 333-165105, 333-172370 and 333-207251) of Alnylam Pharmaceuticals, Inc. of our report dated February 12, 2016 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
February 12, 2016